Elisabeth Marion Schneider
Marion Schneider studied biology and medicine at Bonn University, Germany. Her postdoctoral fellowship was on T-cell deficiencies and stem cell transplantation at the University of Tubingen and HIV1 infection in macrophages and myeloid cells at the Institut Pasteur in Paris (1981–1985), where for the first time she got interested in vacuolization and prolonged viability as well as persistence of macrophages even under conditions of virus infections. Her next topics were hemophagocytic diseases (hemophagocytic lymphohistiocytosis, HLH) and macrophage activation syndromes (MAS) related to immune dysfunction and chronic virus infections as well as severe sepsis and septic shock. When taking the professorship for Experimental Anesthesiology at Ulm University, Ulm, Germany, in 1998, she concentrated on biomarker analysis combining soluble and membrane-bound characteristics of major inflammatory diseases related to inflammasome activation. Inflammation appears to be a major risk factor for sepsis (systemic inflammation) and also for tumor manifestation. In collaboration with the Department of Neurosurgery in the Ulm University, an intense analysis of autophagy has been initiated to overcome the upregulation of autophagy in type IV glioblastoma with novel chemotherapeutic agents.